Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors

Japanese Journal of Clinical Oncology

Volumn 40, Issue 3, 2009, Pages 222-226

  Okamoto, Isamu ^a   Munakata, Masaki ^b   Miyazaki, Masaki ^a   Satoh, Taroh ^a   Takahata, Takenori ^b   Takamatsu, Yasushi ^c   Muto, Osamu ^b   Koike, Kazuhiko ^d   Ishitani, Kunihiko ^d   Mukaiyama, Taketo ^e   Sakata, Yuh ^b   Nakagawa, Kazuhiko ^a   Tamura, Kazuo ^c  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Misawa City Hospital   (Japan)

^c Department of Medicine   (Japan)

^d Higashi Sapporo Hospital   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Growth hormone; Insulin Like growth factor 1; Performance status

Indexed keywords

GROWTH HORMONE; LIOTHYRONINE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYROTROPIN; THYROXINE; THYROXINE BINDING GLOBULIN; HUMAN GROWTH HORMONE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SCORING SYSTEM; SOLID TUMOR; BLOOD; FOLLOW UP; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROGNOSIS; RADIOIMMUNOASSAY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; SURVIVAL RATE; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; TUMOR MARKERS, BIOLOGICAL;

EID: 77950362199     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp155     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 2006;14:999-1011.
3. Ross RJ, Chew SL. Acquired growth hormone resistance. Eur J Endocrinol 1995;132:655-60.
4. Jenkins RC, Ross RJ. Acquired growth hormone resistance in adults. Baillieres Clin Endocrinol Metab 1998;12:315-29.
5. Vance ML, Mauras N. Growth hormone therapy in adults and children. N Engl J Med 1999;341:1206-16.
6. Benjamin F. Growth hormone response to insulin hypoglycemia in endometrial carcinoma. Obstet Gynecol 1974;43:257-61.
7. Pavelic K, Pekic B, Gabrilovac J, Bratic-Mikes V, Boranic M. Hormonal changes in patients with haematological malignancies. Biomedicine 1981;35:181-4.
8. Scheuer A, Grun R, Lehmann FG. Peptide hormones in liver cirrhosis and hepatocellular carcinoma. Oncodev Biol Med 1981;2:1-10.
9. Axelrod L, Halter JB, Cooper DS, Aoki TT, Roussell AM, Bagshaw SL. Hormone levels and fuel flow in patients with weight loss and lung cancer. Evidence for excessive metabolic expenditure and for an adaptive response mediated by a reduced level of 3,5,3′-triiodothyronine. Metabolism 1983;32:924-37.
10. Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985;17:421-4.
11. Tayek JA, Bulcavage L, Chlebowski RT. Relationship of hepatic glucose production to growth hormone and severity of malnutrition in a population with colorectal carcinoma. Cancer Res 1990;50:2119-22.
12. Mazzoccoli G, Giuliani A, Bianco G, De Cata A, Balzanelli M, Carella AM, et al. Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels. Anticancer Res 1999;19:1397-9.
13. Voerman HJ, Strack van Schijndel RJ, Groeneveld AB, de Boer H, Nauta JP, Thijs LG. Pulsatile hormone secretion during severe sepsis: accuracy of different blood sampling regimens. Metabolism 1992;41:934-40.
14. Van den Berghe G, de Zegher F, Lauwers P, Veldhuis JD. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocrinol Metab 1994;79:1141-6.
15. Rondanelli M, Solerte SB, Fioravanti M, Scevola D, Locatelli M, Minoli L, et al. Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 1997;13:1243-9.
16. Michell NP, Dent S, Langman MJ, Eggo MC. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 1997;14:269-77.
17. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997;336:633-40.
18. Laurence J. Growth hormone in HIV/AIDS: current uses and future prospects. Pediatr AIDS HIV Infect 1995;6:281-91.
19. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001;38:443-52.
20. Bentham J, Rodriguez-Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Horm Res 1993;40:87-91.
21. Clemmons DR, Klibanski A, Underwood LE, McArthur JW, Ridgway EC, Beitins IZ, et al. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endocrinol Metab 1981;53:1247-50.
22. Hartman ML, Veldhuis JD, Johnson ML, Lee MM, Alberti KG, Samojlik E, et al. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocrinol Metab 1992;74:757-65.
23. Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study. J Clin Endocrinol Metab 1995;80:2082-7.
24. Huang Q, Nai YJ, Jiang ZW, Li JS. Change of the growth hormone-insulin-like growth factor-I axis in patients with gastrointestinal cancer: related to tumour type and nutritional status. Br J Nutr 2005;93:853-8.
25. Wolf M, Bohm S, Brand M, Kreymann G. Proinflammatory cytokines interleukin 1b and tumor necrosis factor a inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996;135:729-37.
26. Hashizume K, Suzuki S, Komatsu A, Hiramatsu K, Mori J, Yamazaki M, et al. Administration of recombinant human growth hormone normalizes GH-IGF1 axis and improves malnutrition-related disorders in patients with anorexia nervosa. Endocr J 2007;54:319-27.